Hologic, Inc. (NASDAQ: HOLX) is a leading company in the women's health sector, specializing in medical diagnostics and devices. Recently, William Blair downgraded Hologic's stock from "Outperform" to "Market Perform" on October 21, 2025, with the stock priced at $74.19. This change in rating comes amid significant developments involving the company.
Halper Sadeh LLC is investigating the fairness of Hologic's proposed sale to Blackstone and TPG. The deal, valued at up to $18.3 billion, offers Hologic shareholders $76.00 per share in cash. Additionally, shareholders could receive up to $3.00 more per share through a non-tradable contingent value right, paid in two installments of up to $1.50 each.
The acquisition by Blackstone and TPG underscores the strong interest in the medical device sector. The agreement involves purchasing all outstanding shares of Hologic at $76 per share. This transaction highlights the strategic value seen in Hologic's offerings and its position in the healthcare market.
Currently, Hologic's stock is trading at $74.16, marking a 3.18% increase or $2.29 rise. The stock has fluctuated between $74.15 and $74.71 today. Over the past year, HOLX has seen a high of $84.39 and a low of $51.90, with a market capitalization of approximately $16.49 billion.
Today's trading volume for Hologic is notably high at 13.85 million shares. This activity reflects investor interest and the potential impact of the ongoing acquisition discussions. As the situation develops, stakeholders are closely monitoring the outcomes of the investigation and the acquisition process.
